---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-042052"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2026-09-10T10:14:01+00:00"
generated_at: "2026-09-10T10:15:08.198461+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Lipocine to present at H.C. Wainwright 28th Annual Global Investment Conference

## Summary
- Management to present and hold one-on-one meetings at H.C. Wainwright conference in New York, Sept 14-16, 2026.
- Presentation scheduled for Wednesday, September 16, 2026 at 10:00 a.m. ET; webcast archived for 90 days.
- Pipeline includes LPCN 1154 (postpartum depression), LPCN 2201 (MDD), LPCN 2101 (epilepsy), LPCN 2203 (essential tremor), LPCN 2401 (obesity), LPCN 1148 (liver cirrhosis), LPCN 1107 (preterm birth).
- TLANDO (oral testosterone undecanoate) remains FDA-approved for hypogonadism in adult males.

## SEC filing metadata
- accession: 0001493152-26-042052
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2026-09-10T10:14:01+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315226042052/0001493152-26-042052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315226042052/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-042052
- JSON: https://secwatch.observer/filing/0001493152-26-042052.json
- Plain text: https://secwatch.observer/filing/0001493152-26-042052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.